Targeting /xCT Improves Radiofrequency Ablation Efficacy of HCC by Dendritic Cells Mediated Anti-tumor Immune Response

Overview

Journal Imeta

Specialty Biology

Date 2025 Jan 1

PMID 39742309

Authors

Yuzhao Jin

Songhua Cai

Yang Zhou

Dandan Guo

Yuzhen Zeng

Wangting Xu

Yiting Sun

Yueli Shi

Zhiyong Xu

Zaoqu Liu

Peng Luo

Zhao Huang

Bufu Tang

Affiliations

Soon will be listed here.

Abstract

After RFA treatment in patients with liver cancer, the expression of /xCT and the proportion of DCs in the TME were significantly increased. /xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.

Citing Articles

Mesenchymal stem cell-derived extracellular vesicles attenuate ferroptosis in aged hepatic ischemia/reperfusion injury by transferring miR-1275.

Gong Y, You Q, Yuan X, Zeng F, Zhang F, Xiao J Redox Biol. 2025; 81:103556.

PMID: 39986119 PMC: 11893313. DOI: 10.1016/j.redox.2025.103556.

References

Koppula P, Zhang Y, Zhuang L, Gan B . Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018; 38(1):12. PMC: 5993148. DOI: 10.1186/s40880-018-0288-x. View

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

Llovet J, De Baere T, Kulik L, Haber P, Greten T, Meyer T . Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18(5):293-313. DOI: 10.1038/s41575-020-00395-0. View

Glorieux C, Liu S, Trachootham D, Huang P . Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discov. 2024; 23(8):583-606. DOI: 10.1038/s41573-024-00979-4. View

Arensman M, Yang X, Leahy D, Toral-Barza L, Mileski M, Rosfjord E . Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity. Proc Natl Acad Sci U S A. 2019; 116(19):9533-9542. PMC: 6511047. DOI: 10.1073/pnas.1814932116. View

Heras-Murillo I, Adan-Barrientos I, Galan M, Wculek S, Sancho D . Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024; 21(4):257-277. DOI: 10.1038/s41571-024-00859-1. View

Nault J, Sutter O, Nahon P, Ganne-Carrie N, Seror O . Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol. 2017; 68(4):783-797. DOI: 10.1016/j.jhep.2017.10.004. View

Qi X, Yang M, Ma L, Sauer M, Avella D, Kaifi J . Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. J Immunother Cancer. 2020; 8(2). PMC: 7594543. DOI: 10.1136/jitc-2020-001038. View

Kang T, Lim H, Cha D . Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma. Clin Mol Hepatol. 2017; 23(1):95-101. PMC: 5381839. DOI: 10.3350/cmh.2017.0006. View

10.

Maier B, Leader A, Chen S, Tung N, Chang C, LeBerichel J . A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020; 580(7802):257-262. PMC: 7787191. DOI: 10.1038/s41586-020-2134-y. View

11.

Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X . PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res. 2016; 22(5):1173-1184. PMC: 4780056. DOI: 10.1158/1078-0432.CCR-15-1352. View

12.

Ali M, Grimm C, Ritter M, Mohr L, Allgaier H, Weth R . Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol. 2005; 43(5):817-22. DOI: 10.1016/j.jhep.2005.04.016. View

13.

Yan Y, Teng H, Hang Q, Kondiparthi L, Lei G, Horbath A . SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nat Commun. 2023; 14(1):3673. PMC: 10281978. DOI: 10.1038/s41467-023-39401-9. View

14.

Magen A, Hamon P, Fiaschi N, Soong B, Park M, Mattiuz R . Intratumoral dendritic cell-CD4 T helper cell niches enable CD8 T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med. 2023; 29(6):1389-1399. PMC: 11027932. DOI: 10.1038/s41591-023-02345-0. View